Sign inThe trial showed statistically significant progression-free and overall survival gains for ORPATHYS plus TAGRISSO versus chemotherapy in MET-driven resistant NSCLC.
SEC filing
The trial hit its primary endpoint in patients with IMNM and dermatomyositis, with argenx citing significant improvement over placebo at Week 52.
SEC filing
The company enrolled and treated 350 patients in the pivotal MSB-DR004 study, setting up a mid-2027 readout.
SEC filing
The combined company will focus on Slate's migraine pipeline and raise $245 million in a private placement to fund operations into 2029.
SEC filing
New mechanistic findings announced August 17, 2026 back the design of an upcoming Phase IIb pancreatic cancer study following prior Phase IIa results.
SEC filing
The Phase III study was stopped after monitors found the combination unlikely to beat pembrolizumab on survival measures in low PD-L1 patients.
SEC filing
An 8-K/A says the UDC transaction was not a business combination after all, so no historical or pro forma financials are required.
SEC filing
Coherus signed a new senior secured term loan facility on August 12, 2026, and used the proceeds to repay and terminate its prior loan agreement.
SEC filing
The collaboration, announced August 17, 2026, will pair Trinovium's fluid technology with Echelon's hyperscale data center infrastructure to develop liquid cooling systems for AI computing.
SEC filing
BridgeBio Pharma will not receive proceeds as its selling stockholder offloads 5,000,000 shares in a deal expected to close August 17, 2026.
SEC filing
The consumer health company appointed the veteran Wall Street analyst to its board on August 17, 2026, ahead of second-quarter earnings the following day.
SEC filing
The company's June 30, 2026 quarterly report cites a $2.5 million six-month net loss and a working capital deficit, while a planned partial spinoff of subsidiary BioKey Cayman has been pushed back.
SEC filing (4)
The company also removed CEO Michael Handley, elevated CFO Lisa Wolf to add the COO title, and disclosed preliminary special meeting vote results.
SEC filing
The San Diego dermatology company said insiders including its CEO and CFO are participating in the at-the-market priced deal, set to close August 18, 2026.
SEC filing
NRx said FDA raised no drug-related deficiencies in its ketamine ANDA review and disclosed a DARPA prime contract for a Phase 2/3 trial of NRX-101 with robotic TMS.
SEC filing
The two appointments, effective August 13, 2026, rebalance board classes as Maze advances its kidney and metabolic disease pipeline toward late-stage development.
SEC filing
Adial says it remains on track to file an IND for its ulcerative colitis candidate AT177 in the first half of 2027 after acquiring Azora Therapeutics.
SEC filing
The Alabama healthcare services company filed a Form D on August 17, 2026, reporting one investor in an equity raise under a Rule 506(b) exemption.
SEC filing
Lantern's Q2 2026 update covers a new AI subsidiary, an EGFR L858R lung cancer data update, an EMA-cleared bladder cancer trial, and $7.4 million in cash.
SEC filing
The company said topline results confirmed the prodrug design of its next-generation STAT3 inhibitor and plans an IND-enabled UC trial start in 2027.
SEC filing
Quoin Pharmaceuticals said the FDA cleared its IND for Peeling Skin Syndrome after quarter end, setting up a Phase 2/3 study to start in the second half of 2026.
SEC filing
The company reported 850 patients enrolled, above its original target, with topline data still expected in early 2027.
SEC filing
The company reported $7.1 million in nine-month LYMPHIR revenue and $17 million in cash, while citing early-stage data expanding the drug's potential use beyond cutaneous T-cell lymphoma.
SEC filing
The company finished enrolling ovarian cancer patients for its Phase 2 monotherapy primary analysis and reported $79.4 million in cash as of June 30, 2026.
SEC filing
The company reported second-quarter 2026 results and said it reached agreement with the FDA on key elements of a registrational Phase 3 trial, with protocol submission expected in the third quarter.
SEC filing
Dyadic International sold 3,625,000 shares in a registered direct offering alongside warrants for the same number of shares in a private placement, closing August 14, 2026.
SEC filing (2)
Clene said it plans to submit an accelerated approval application for CNM-Au8 in ALS in early fourth quarter 2026, citing new survival data tied to a nerve-damage biomarker.
SEC filing
The company highlighted ASCO and AACR data supporting Plinabulin and confirmed a July 1 leadership change as it works toward starting the Phase 3 DUBLIN-4 trial.
SEC filing
Zerillo informed the company of his retirement plans, with his departure from all roles set for August 14, 2026.
SEC filing
Cue disclosed a food allergy IND submission for CUE-221, a completed $50 million private placement, and higher quarterly expenses tied to a licensing deal, with cash of $17.4 million at quarter end.
SEC filing
The Watertown biopharma reported $116.8 million in cash and outlined pipeline milestones for NMRA-215, NMRA-511, and NMRA-898 through 2026.
SEC filing
The company said complete remission rates were at least three times higher than control in the first 45 patients, with 90-patient enrollment still targeted for September 2026.
SEC filing
The San Antonio diagnostics company sold pre-funded warrants and companion warrants to an institutional investor, closing the deal on August 14, 2026.
SEC filing
The company said it continued IND-enabling work on its lead candidate EB-003 and reported preclinical data supporting a non-hallucinogenic profile ahead of a planned Phase 1 trial.
SEC filing
Melrose, Massachusetts biotech Harton, Inc. reported raising $15.1 million of an $18.1 million equity offering from five investors, per an SEC filing dated August 14, 2026.
SEC filing
The Dublin-based diagnostics company disclosed the funding amendment and Nasdaq notice in a 6-K dated August 14, 2026.
SEC filing
The company reported second quarter 2026 results alongside a completed Phase 3-ready manufacturing run, a new patent through 2042, and in-house diagnostic testing capability.
SEC filing
Jasper closed its acquisition of Kira Pharmaceuticals in July, raised $132 million in a concurrent private placement, and laid out 2026-2027 milestones for its three lead programs.
SEC filing
The company can sell shares periodically through Jefferies under a deal dated August 14, 2026, with proceeds earmarked mainly for its smoking-cessation drug program.
SEC filing
Silexion initiated its Phase 2/3 pancreatic cancer trial in Israel after German regulatory clearance, while cash fell to $2.2 million and it closed a $2.5 million offering.
SEC filing
The clinical-stage biopharma will sell 23 million shares to help fund its WEE1 inhibitor azenosertib through ongoing ovarian cancer trials.
SEC filing (2)
Vistagen reported fiscal Q1 2027 results and said it plans to meet with the FDA this quarter to discuss a possible Phase 3 path for fasedienol in social anxiety disorder.
SEC filing
The company said 44 institutions have ordered LYMPHIR since launch, with institutional vial orders up 31% sequentially and $7.1 million in nine-month revenue.
SEC filing
Aptevo said dose optimization for mipletamig should finish by year end 2026, ahead of a planned Phase 2 regulatory interaction in the first quarter of 2027.
SEC filing